$MESO News

Reported Earlier, Mesoblast Reaches Patient Recruitment Target In Phase 3 Trial For Non-Opioid Chronic Low Back Pain Therapy

Reported Earlier, Mesoblast Acquires Exclusive Worldwide License To Mayo Clinic-Developed CAR Technology Platform To Boost Effectiveness Of MSC Products For Inflammatory Diseases

Mesoblast Limited: A Risk/Reward Story

Mesoblast Receives Investigational New Drug Clearance From FDA For Registrational Clinical Trial For Duchenne Muscular Dystrophy Treatment Ryoncil

Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript

Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade)

Reported Earlier, Mesoblast's FDA-Approved Ryoncil Gets IND Clearance For Registrational DMD Trial, To Randomize 76 Patients Aged 5-9 Years Across 7 Infusions Over 9 Months

Reported Earlier, Mesoblast Reports $30.3M In Ryoncil Net Sales For March Quarter As Strong February And March Growth Offsets January Holiday Seasonality

Mesoblast shares are trading lower after the company reported worse-than-expected Q4 sales results.

Mesoblast H1 EPS $(0.03) Beats $(0.20) Estimate, Sales $51.342M Miss $72.000M Estimate

Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript

What's Next: Mesoblast's Earnings Preview

Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy

Reported Earlier, Mesoblast Data Shows 15% Early Mortality In Third-Line Ryoncil Treatment Versus 2% In Second-Line Phase 3 Trial Emphasizing Earlier Use Importance

High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

Mesoblast: Real-World Data Validates The Bull Case For Ryoncil

ASX Growth Companies With High Insider Stakes To Watch

Reported Earlier, Mesoblast Highlights Ryoncil Net Revenues Of $30M With Strong Sales Momentum And Enhanced Strategic Optionality

Ryoncil® Net Revenues Increase for the Quarter to US$30M

Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication